BN-201; small molecule for Neuromyelytis Optica & progressive MS

                   
  • Product Overview: First in class SGK agonist for neurodegenerative diseases
  •        
  • Primary Indications; Rare diseases of the eye - Neuromyelitis Optica, (NMO) & acute optical neuritis (AON). Orphan conditions
  •        
  • Secondary Indications: Multiple Sclerosis, including progressive (SPMS and PPMS)
  •        
  • Core differentiator(s):                 
                     
    • Primary neuroprotective agent which prevents axonal loss and neuronal death in several animal models driven by different mechanisms of damage, including demyelination, inflammation and hypertension;
    •        
    • Promotes remyelination
    •        
                           
  • Development stage; Phase 1
  • Opportunity: Available for license collaboration and investment; (Series B round in progress)
  •